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Abstract
Objectives:
The objectives were to estimate the prevalence of self-treated hypoglycaemia in patients using basal insulin
analogues; identify demographic, treatment related and behavioural risk factors; and describe patient and
physician responses to these events.
Research design and methods:
The GAPP2 (Global Attitude of Patients and Physicians 2) study was an online multinational cross-sectional
study of patients with type 2 diabetes currently treated with basal insulin, and healthcare professionals
involved in the care of such patients. The primary variable of interest was self-treated hypoglycaemia within
the last 30 days.
Results:
A total of 3042 patients treated with basal insulin analogues and 1222 prescribers completed the full survey.
Overall, 36% of patients had experienced self-treated hypoglycaemia during the previous 30 days. In
response to self-treated hypoglycaemia, patients reported missing (7%), reducing (11%) or mistiming
(4%) basal insulin doses, increasing the level of glucose monitoring (40%) or utilising healthcare
resources (7%). Patients reporting irregular basal insulin dosing by missing, mistiming or reducing a
dose were also significantly more likely to report an episode of self-treated hypoglycaemia in the same
time period: 41% versus 34% (p¼ 0.004), 43% versus 33% (p50.001), and 56% versus 32%
(p50.001) respectively. Nocturnal events worried significantly more patients than diurnal events (42%
versus 23%, p50.001). Patient worry about hypoglycaemia, insulin regimen and reduced basal dosing
were identified as the key differentiating variables associated with increased risk of self-treated
hypoglycaemic events. Most prescribers (76%) believed that insulin analogues minimised the risk of
nocturnal hypoglycaemia when compared to NPH insulin; 46% also reported being contacted at least
once a month by insulin analogue patients after self-treated hypoglycaemic events.
Conclusions:
Self-treated hypoglycaemia is common in approximately one third of patients using insulin analogue
regimens. Additionally, self-treated hypoglycaemia was found to be associated with clinically significant
effects on patient well-being and functioning, patient and physician management and healthcare utilisation
despite the potential limitations of an online self-complete survey such as the need to be topic focused, the
potential for under-reporting and social bias.
Introduction
Insulin is recognised as the most effective blood glucose lowering treatment in
type 2 diabetes mellitus (T2DM)1 and its initiation, historically the province
of specialists, is increasingly being undertaken by primary care physicians2,3.
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Insulin is also widely considered to be the most challenging
and time consuming diabetes management approach and
self-treated hypoglycaemia, often referred to as minor
hypoglycaemia, remains a key consideration4,5. The usual
symptoms of hypoglycaemia include a pounding heart,
trembling, hunger, sweating, difficulty in concentrating
and confusion6 and these minor hypoglycaemic episodes
may precede events where patients are unable to treat
themselves (severe hypoglycaemic events)7.
The ongoing interruption to insulin usage related to
hypoglycaemic episodes can create a barrier to optimal
long-term glycaemic control of patients with T2DM8–10,
and is a substantial, independent cause of excess morbidity
resulting in increased costs of T2DM for the patient,
employers and society as a whole8,9. Additionally, self-
treated hypoglycaemia can have a significant impact on
diabetes management, patient functioning and productiv-
ity8,9. Patients who experience hypoglycaemia have been
found to be more affected by their diabetes than those who
do not experience these events, and often report lower
general health indicating that a reduction of the symptoms
of hypoglycaemia may be pertinent to improving patient
well-being as well as providing potential cost reductions in
overall diabetes management11.
Self-treated hypoglycaemia is inadequately charac-
terised in people with T2DM, most particularly those
using insulin analogues. A broad link between hypoglycae-
mia and insulin adherence may be postulated; however,
there is currently little specific data examining this poten-
tial association12. Moreover, while insulin analogue use is
common and has been shown to lower the risk of hypogly-
caemia, particularly nocturnal hypoglycaemia, compared
to neutral protamine Hagedorn (NPH) insulin13 as well as
provide short-term cost effectiveness on the management
of hypoglycaemia in a type 1 patient (T1DM) popula-
tion14, there is an absence of real world data specifically
on the impact of insulin analogues on self-treated hypogly-
caemia in T2DM. Further, there is no data on the relation-
ship between these events and dosing irregularities which
may either contribute to or be the result of these events.
The objectives of the current study were to estimate the
incidence of self-treated hypoglycaemia in patients using
basal insulin analogues; examine attributes of disease his-
tory and management including dosing irregularities,
patient behaviours, and patient perceptions that may be
associated with an increased incidence of hypoglycaemia
and thus provide a clinically useful profile of patients at
risk; and describe patients’ and physicians’, including pri-
mary care providers’, responses to episodes of self-treated
hypoglycaemia.
Methods
The GAPP2 (Global Attitudes of Patients and
Physicians 2) survey was an online multinational,
cross-sectional study of T2DM patients using insulin and
physicians (specialists and GPs) managing this condition.
The survey was conducted in the US, Canada, Japan,
Germany, UK, and Denmark.
Survey development, structure and design
The items for the questionnaires for both patients and
physicians were generated from multiple data sources: an
international steering committee of diabetes clinical
experts; the current literature on dosing irregularities and
self-treated hypoglycaemia; and from identifying key con-
cepts and themes from transcripts of nine previously con-
ducted focus groups and interviews with diabetes patients.
The content validity was based on prior focus group data.
Prior to the full launch, both surveys were pilot tested
in a two-step process. First, both surveys were cognitively
debriefed to ensure comprehension and readability by a
small sample of pre-recruited respondents who completed
the online survey in the presence of a native speaking
researcher in each participating country. Minor edits to
some items (that did not affect the question asked) were
made at this stage, such as the inclusion of don’t know/
can’t remember option or edits to specify the need for an
answer in percentages rather than whole numbers. Second,
after this refinement 50–100 respondents per country were
then invited to each survey. After completing the first 10
surveys, the data and survey mechanism were tested for
sense and logic, before invitations were distributed to
other research panel members.
Questionnaires to patients (90 items) and physicians
(58 items) were structured in the same way to ease
between-population comparisons, covering demographics
and background, diabetes management, self-treated hypo-
glycaemia and patient functioning and well-being.
The patient definition of self-treated hypoglycaemia was:
symptoms of low blood sugar such as sweating, weakness,
trembling, and difficulty concentrating, which could be
self-treated (for example by drinking a glass of juice,
eating something, or taking a sugar pill); and the physician
definition was: low blood sugar events that the patients can
treat themselves, i.e. without medical assistance. When
asked about their responses to self-treated hypoglycaemia
patients were not asked whether they had or had not been
advised to alter their insulin taking behaviour by a health-
care professional as the survey was intended to capture the
patient perspective regarding their adherence behaviour.
With regard to response after a hypoglycaemic event it was
generally assumed that missed/mistimed basal doses would
be considered against healthcare professional advice based
on common clinical practice whereas reduced basal doses
may often be considered in line with clinical
recommendations.
Current Medical Research & Opinion Volume 28, Number 12 December 2012
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The surveys were online self-complete questionnaires
which used an adaptive question approach to minimise
unnecessary questions and shorten completion times.
Questionnaires were translated into the native language
of respondents. Additionally, to minimise the impact of
recall bias on patient responses, reporting of self-treated
hypoglycaemia was focused on events occurring during the
last 30 days and respondents were also offered a ‘don’t
know’ answer to avoid forcing inaccurate responses.
Recruitment
Participants were recruited from pre-existing general
public and healthcare professional online research
panels. These panels were identified via an independent
research company (Bryter Limited) who contracted com-
mercial research panels such as Research Now, GMI/
Lightspeed andWorldOne etc. The panels were comprised
of a representative sample of the online population as a
whole for each country in order not to bias the sample to
any particular demographic group or respondent profile.
Members were recruited from a broad array of online and
offline approaches that best represent the local online
community as a whole within each country. Recruitment
techniques include banner placements on websites, email
campaigns, online advertising, blogs, social media, refer-
rals through existing panel members, affiliate marketing
(including TV/print) and text (SMS) mobile campaigns.
The healthcare professional research panel consists of
more than 600,000 members in the countries surveyed.
Physicians were contacted by email and provided with a
unique uniform resource locator (URL) enabling entry to
the online survey. Invitations were initially targeted by
pre-registered speciality. Physicians responding to the
invitation were then screened to ensure they met the
entry criteria in terms of minimum number of years qual-
ified within their current speciality (two years), minimum
number of T2DM patients seen in a typical month (20 for
primary care physicians (5 in Denmark and Japan) and 40
for diabetes specialists (20 in Denmark and 30 in Japan) to
reflect the national situation, of which at least 10 must
have been treated with insulin analogues (10 every 3
months in Denmark and Japan). Incentives equivalent of
£1 to £3 per minute were offered in line with local rules
and regulations, which were often non-monetary.
Patient participants were recruited from established
online general population research panels with over 6.5
million members within the countries surveyed.
Potential patients were initially contacted on the basis of
previous survey evidence of diabetes and age. To be eligi-
ble for survey inclusion, patients were required to have
been diagnosed with T2DM by a healthcare professional,
be aged 40 years or more and to have been diagnosed as
having T2DM over the age of 40 (self-report). Patients had
to be currently treated using insulin medication, excluding
those using premix insulin treatments, those on bolus only
insulin or those using insulin pumps. Respondents meeting
these entry criteria were also asked whether their insu-
lin(s) were cloudy in appearance to differentiate between
basal insulin analogues and NPH. Specific product names
were not collected.
Statistical analysis
The primary variables reported in this paper focus on self-
treated hypoglycaemia and its impact on T2DM manage-
ment. Patient reported variables included: self-treated
hypoglycaemia (frequency, day-time/night-time), reported
behaviour in response to self-treated hypoglycaemia
including basal insulin dosing irregularities (missed, mis-
timed [defined as dosing2 hours from the prescribed time
in the respondents’ judgement] and/or reduced doses),
impact on healthcare resource utilisation and patients’
attitudes to self-treated hypoglycaemia and their impact
on patient functioning and well-being.
Prescriber reported variables included: healthcare utili-
sation in response to self-treated hypoglycaemia, insulin
initiation behaviour due to self-treated hypoglycaemia
risk, and clinician response to patient-reported self-treated
hypoglycaemia.
Data were stored in compliance with the UK Data
Protection Act (1998) on secure servers and each respon-
dent was issued with a unique URL, which could be used
once to access the questionnaire. Collected data from the
survey was stored by the research company separately from
any personal or contact information and electronic data
was de-identified with respondents identified by study ID
(RESPID) only. Investigators did not have access to any
respondents’ personal details and data was analysed on an
aggregated level.
All data were logic tested to ensure that respondents did
not provide contradictory answers and data identified elec-
tronically as being incomplete (defined as responses that
did not reach the end of the survey) was collected but not
processed or included in analysis. Responses to the survey
were not checked against patient records or direct
observations.
Data was descriptively analysed using mean and range
or standard deviation (as stated) for continuous data and
frequency (percentage) for categorical variables. Group
comparisons were made using the unpaired t-test or
Pearson’s chi square test, where appropriate. Significance
was set at alpha¼ 0.05. Outliers were defined as values
lying more than 1.5 interquartile ranges (IQRs) below
the first quartile or above the third quartile; and in
instances where outlying values exhibited a large degree
of influence on the parameter of interest (as assessed by
Current Medical Research & Opinion Volume 28, Number 12 December 2012
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Cook’s distance), these values were removed from the
analysis.
Chi-squared Automatic Interaction Detection
(CHAID) analysis15 was employed to identify combina-
tions of patient characteristics most highly associated
with the incidence of self-treated hypoglycaemia.
CHAID evaluates all of the values of potentially associated
variables using a decision tree format. Values that are
judged to be statistically similar with respect to the
target variable are merged and dissimilar variables are
maintained. The most strongly associated variable, differ-
entiating patients at higher risk from those at lower risk, is
then selected to form the highest branch in the decision
tree and this process continues recursively until comple-
tion of a decision tree. The CHAID tree branches show the
proportion of total events (top section of the boxes) and
proportion of patients (bottom section of the boxes).
In order to construct the decision tree, factors from the
survey were grouped according to four conceptual domains
to provide a structure and informed analysis framework:
(1) disease history and management (duration of diabetes,
diabetes specific co-morbidity, non-insulin antidiabetes
treatments, duration of insulin therapy, insulin regimen,
current method of basal insulin administration, number of
insulin injections per day, and number of visits to a health-
care professional in the last 12 months); (2) patient behav-
iours (missed, mistimed or reduced basal insulin doses in
the last 30 days; (3) patient perceptions (perceived diabe-
tes control, basal insulin inconvenience, and the extent to
which basal insulin interferes with lifestyle and activity,
patient satisfaction with current basal insulin treatment,
patient comfort with taking insulin, patient guilt or worry
about missed doses, patient downplaying or hiding missed
doses from healthcare professionals, worry about hypogly-
caemia; and (4) patient attributes (age at diagnosis,
current age, gender, BMI, current working situation, edu-
cational level, lifestyle activity and eating meals at regular
times). Hypoglycaemia was defined as an ordinal outcome
with three possible outcomes: no events (0), one to three
events in the previous 30 days (1), and four or more events
in the previous 30 days (2). Bonferroni adjustment was
used to correct for the number of different ways that the
categories in a single predictor variable can be merged.
Results
Participants and demographics
A total of 1,034,363 individuals (from general population
research panels) were invited to participate in the patient
survey, of which 101,449 responded and were screened
(response rate 9.8%). These general population respon-
dents produced 13,057 eligible patients who met the pre-
specified entry criteria, of whom 3587 eligible respondents
went on to complete the full survey (Figure 1). A total of
36,240 healthcare professionals were invited to participate
in the survey, of whom 5115 responded and 1653 com-
pleted the study (Figure 1). In this paper, data are pre-
sented on 3042 T2DM patients taking insulin analogues
and 1222 physicians. No outlier values were identified in
reported variables.
Patient and prescriber demographics are summarised
in Table 1.
Incidence of self-treated hypoglycaemia
Overall, 36% of respondents had experienced self-treated
hypoglycaemia during the previous 30 days, 30%
experiencing a daytime event and 13% a nocturnal
event (Table 2). Patients using more complex regimens
(basal and bolus insulin regimens) were more likely to
have reported self-treated hypoglycaemia, with a greater
proportion of these patients also reporting having five or
more self-treated episodes (Table 3).
Patient reported impact of self-treated
hypoglycaemia on diabetes management
Patients reported responding to self-treated hypoglycaemic
events. Seven percent of patients said that they had
missed, 11% said they had reduced and 4% said they had
mistimed their basal insulin dose. Additionally, 40% said
that they had increased their level of glucose monitoring.
A small proportion of patients (7%) reported utilising
healthcare resources available to them (Table 4).
Patients who reported dosing their basal insulin irregu-
larly by missing, mistiming or reducing a dose were also
significantly more likely to report an episode of self-treated
hypoglycaemia in the same time period (41% versus 34%
(p¼ 0.004), 43% versus 33% (p50.001), and 56% versus
32% (p50.001) respectively.
Furthermore, to reduce their risk of nocturnal hypogly-
caemia, patients reported that they had intentionally let
their blood glucose go high (14%) or had not taken their
insulin as prescribed (16%).
Patient reported impact of self-treated
hypoglycaemia on functioning and well-being
Self-treated hypoglycaemia also had a substantial effect on
patient functioning and well-being. In particular, it
impacted negatively on patients’ ability to focus and
concentrate, or carry out spontaneous activities, such as
playing sport/exercising or changing plans (Figure 2).
Patients were especially concerned about experiencing a
hypoglycaemic event where they had no easy access to
food or drink, or while sleeping or driving. Nocturnal
events also worried significantly more patients than
Current Medical Research & Opinion Volume 28, Number 12 December 2012
4 Impact of self-treated hypoglycaemia in type 2 diabetes Brod et al. www.cmrojournal.com ! 2012 Informa UK Ltd
Cu
rr 
M
ed
 R
es
 O
pi
n 
D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
N
ov
o 
N
or
di
sk
 A
/S
 o
n 
11
/1
5/
12
Fo
r p
er
so
na
l u
se
 o
nl
y.
diurnal events (42% versus 23%, p50.001) with 69%
saying they worried to some degree and over half (57%)
being concerned about the potential negative impact of
nocturnal events on their long-term health.
Physician reported impact of self-treated
hypoglycaemia on diabetes management
When questioned about their beliefs about currently
available insulin therapies, the prescriber cohort believed
that insulin analogues minimised the risk of hypoglycae-
mia when compared to NPH insulin: 76% agreed insulin
analogues were better at minimising the risk of nocturnal
hypoglycaemia and 71% agreed insulin analogues were
better at minimising diurnal hypoglycaemic events.
Physicians reported an impact of self-treated hypogly-
caemia on resource utilisation and disease management:
46% of physicians reported being contacted at least once a
month by insulin analogue patients after these events.
Additionally, 83% of physicians reported that they consid-
ered hypoglycaemic risk when choosing the type of insulin
on which to initiate patients and 56% started patients on
a lower insulin dose than recommended due to risk of
hypoglycaemic events. Physicians reported that on most
occasions they advised patients who had a number of
hypoglycaemic episodes to increase their blood glucose
monitoring (29%), temporarily reduce their basal insulin
dose (19%), reduce basal insulin long-term (15%) or split
their basal insulin dose (3%) (Figure 3).
CHAID analysis: patient characteristics
associated with a greater likelihood of
experiencing self-treated hypoglycaemia
As shown in Figure 4, the amount of worry about hypogly-
caemia (as defined by the number of situations that
patients reported worrying about these episodes) was iden-
tified as the variable most individually associated with the
number of hypoglycaemic events, and was therefore the
primary differentiator in the top branch in the CHAID
tree. In contrast, those who did not worry (worried about
0 situations) were shown to be at the least risk of
hypoglycaemia.
For patients with only minor worry (worry in 1–3 situ-
ations) their hypoglycaemia risk profile was greatest if they
reduced their basal insulin dose regardless of insulin regi-
men or if they were on a basal only regime and had not
reduced a basal dose. Those with moderate worry (worry in
4–5 situations) were more likely to have self-treated hypo-
glycaemia if they had reduced a dose of basal insulin or if
they were female and had not reduced a basal dose in the
last 30 days. In those patients with the most worry (6–9
1,070,603 invitations
sent to participate in 
the survey
36,240 HCPs invited
5,115 HCPs responded
2,667 HPCs entered
the survey
1,653 complete HCP
responses received
1,222 complete
primary care and
specialist responses
received
431 completed 
diabetes nurses 
and educator 
responses received
1,014 incomplete
HCP responses
received
(not analysed)
2,448 HCPs
screened out
31,305 HCPs did 
not respond
1,034,363 sample of 
general population
invited 
101,499 sample of 
general population
responded
13,057 patients
entered the survey
3,587 complete 
patient responses
received
3,042 complete insulin
analogue patient
responses received
545 complete NPH
insulin patient
responses received
9,470 incomplete
patient responses
received 
(not analysed)
88,392 sample of 
general population
screened out
932,864 sample of 
general population
did not respond
Figure 1. Patient and healthcare professional survey recruitment flow diagram.
Current Medical Research & Opinion Volume 28, Number 12 December 2012
! 2012 Informa UK Ltd www.cmrojournal.com Impact of self-treated hypoglycaemia in type 2 diabetes Brod et al. 5
Cu
rr 
M
ed
 R
es
 O
pi
n 
D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
N
ov
o 
N
or
di
sk
 A
/S
 o
n 
11
/1
5/
12
Fo
r p
er
so
na
l u
se
 o
nl
y.
Ta
bl
e
1.
Pa
tie
nt
an
d
pr
es
cr
ib
er
de
m
og
ra
ph
ic
s.
G
lo
ba
l
U
S
A
C
an
ad
a
Ja
pa
n
U
K
D
en
m
ar
k
G
er
m
an
y
P
A
TI
EN
TS
B
as
e
(n
)
30
42
18
50
15
6
35
5
32
2
57
30
2
A
ge
(y
ea
rs
)
61
(8
.1
2)
62
(7
.6
3)
60
(8
.2
6)
57
(8
.1
2)
60
(8
.6
3)
62
(8
.2
7)
57
(7
.7
5)
M
al
e
(%
)
59
%
50
%
54
%
85
%
67
%
65
%
70
%
D
ur
at
io
n
of
di
ab
et
es
(y
ea
rs
)
11
(6
.7
0)
12
(6
.5
6)
12
(8
.0
5)
10
(6
.8
7)
11
(6
.4
5)
11
.7
(6
.4
7)
9
(5
.9
4)
B
M
I
(k
g/
m
2
)
34
(1
9.
22
)
36
(1
9.
37
)
38
(3
0.
75
)
26
(1
3.
71
)
32
(1
7.
84
)
35
(3
3.
89
)
32
(7
.4
2)
N
um
be
r
of
di
ab
et
es
co
m
pl
ic
at
io
ns
(1
3
lis
te
d)
–
m
ed
ia
n
(r
an
ge
)
2
(0
–
13
)
2
(0
–
10
)
2
(0
–
11
)
1
(0
–
13
)
3
(0
–
10
)
3
(0
–
8)
3
(0
–
9)
D
ur
at
io
n
of
in
su
lin
tr
ea
tm
en
t
(y
ea
rs
)
5
(4
.4
4)
5
(4
.4
6)
5
(4
.9
2)
5
(4
.2
8)
5
(4
.2
8)
7
(5
.8
0)
5
(4
.0
3)
In
su
lin
re
gi
m
en
B
as
al
on
ly
48
%
51
%
50
%
43
%
52
%
51
%
33
%
B
as
al
–
bo
lu
s
52
%
49
%
50
%
57
%
48
%
49
%
67
%
N
um
be
r
of
ba
sa
l
in
je
ct
io
ns
pe
r
da
y
1.
3
(1
.2
1)
1.
3
(1
.0
4)
(1
.3
(0
.5
7)
1.
3
(0
.7
5)
1.
3
(0
.6
9)
1.
4
(0
.7
7)
1.
7
(2
.6
0)
In
je
ct
io
n
de
vi
ce
ba
sa
l
in
su
lin
(%
)
Pr
ef
ill
ed
pe
ns
61
%
54
%
47
%
90
%
77
%
77
%
53
%
A
vi
al
an
d
sy
ri
ng
e
33
%
49
%
8%
6%
5%
12
%
14
%
R
ef
ill
ab
le
pe
ns
11
%
2%
49
%
7%
20
%
12
%
41
%
Ed
uc
at
io
n
S
om
e
hi
gh
sc
ho
ol
3%
1%
1%
2%
14
%
5%
5%
H
ig
h
sc
ho
ol
gr
ad
ua
te
23
%
21
%
14
%
32
%
22
%
14
%
32
%
S
om
e
co
lle
ge
(n
o
de
gr
ee
)
23
%
29
%
17
%
17
%
12
%
5%
8%
C
ol
le
ge
(d
eg
re
e)
37
%
35
%
34
%
49
%
43
%
63
%
36
%
M
as
te
rs
/P
hD
/p
os
t
do
ct
or
at
e
13
%
14
%
34
%
-
7%
6%
17
%
W
or
ki
ng
(%
)
36
%
28
%
40
%
65
%
33
%
32
%
44
%
Li
vi
ng
al
on
e
(%
)
22
%
23
%
29
%
11
%
21
%
21
%
26
%
P
er
ce
iv
ed
di
ab
et
es
co
nt
ro
l
(%
)
Po
or
10
%
10
%
7%
21
%
6%
4%
5%
M
od
er
at
e
56
%
58
%
54
%
64
%
53
%
39
%
39
%
G
oo
d
34
%
32
%
38
%
15
%
41
%
58
%
56
%
P
H
Y
S
IC
IA
N
S
B
as
e
(n
)
12
22
31
1
20
2
22
2
20
8
70
20
9
Ti
m
e
si
nc
e
qu
al
if
ie
d
(y
ea
rs
)
17
(8
.1
7)
17
(7
.6
6)
21
(8
.4
6)
16
(8
.5
4)
14
(7
.2
7)
18
(9
.3
9)
14
(6
.3
2)
S
pe
ci
al
ty
Pr
im
ar
y
ca
re
55
%
51
%
79
%
40
%
50
%
73
%
51
%
S
pe
ci
al
is
t
45
%
49
%
21
%
60
%
50
%
27
%
49
%
A
ve
ra
ge
nu
m
be
r
of
in
su
lin
tr
ea
te
d
pa
ti
en
ts
w
it
h
T2
D
M
ag
ed
40
þ
Pr
im
ar
y
ca
re
67
(6
3.
42
)
89
(6
7.
44
)
80
(7
3.
29
)
27
(2
1.
30
)
70
(6
0.
30
)
26
(1
5.
93
)
73
(5
9.
91
)
S
pe
ci
al
is
t
14
7
(1
12
.0
2)
16
5
(1
01
.4
8)
13
0
(8
1.
01
)
11
3
(1
25
.6
8)
13
0
(8
9.
05
)
69
(2
8.
87
)
19
7
(1
26
.4
1)
P
er
ce
nt
ag
e
of
in
su
lin
tr
ea
te
d
pa
ti
en
ts
w
it
h
T2
D
M
us
in
g
an
al
og
ue
in
su
lin
(%
)
73
%
79
%
65
%
82
%
70
%
67
%
65
%
Ty
pe
of
in
su
lin
an
al
og
ue
s
us
ed
(%
)
B
as
al
–
bo
lu
s
ta
ke
n
se
pa
ra
te
ly
31
%
34
%
32
%
27
%
28
%
19
%
34
%
Pr
em
ix
22
%
15
%
20
%
33
%
27
%
30
%
17
%
B
ol
us
on
ly
11
%
8%
10
%
13
%
10
%
5%
15
%
B
as
al
on
ly
36
%
42
%
38
%
27
%
35
%
47
%
33
%
O
th
er
0%
0%
0%
1%
0%
0%
1%
Current Medical Research & Opinion Volume 28, Number 12 December 2012
6 Impact of self-treated hypoglycaemia in type 2 diabetes Brod et al. www.cmrojournal.com ! 2012 Informa UK Ltd
Cu
rr 
M
ed
 R
es
 O
pi
n 
D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
N
ov
o 
N
or
di
sk
 A
/S
 o
n 
11
/1
5/
12
Fo
r p
er
so
na
l u
se
 o
nl
y.
Table 4. Behaviours in response to self-treated hypoglycaemia, and utilisation of healthcare resources in past
30 days.
Reporting of self-treated
hypoglycaemia
Behavioural Response
Base (n) 1042
Missed Doses
Proportion of patients 7%
Number of missed doses 2 (1–10)
Mistimed Doses
Proportion of patients 4%
Number of mistimed doses 1.8 (1–4)
Reduced Doses
Proportion of patients 11%
Number of reduced doses 2.4 (1–16)
Increased level of blood glucose monitoring 40%
Healthcare Utilisation
Unplanned trip to see a GP/PCP 2%
Unplanned trip to see a diabetes specialist 1%
Unplanned trip to a hospital emergency department 51%
Emailed a healthcare professional e.g. your doctor 1%
Searched for information/advice online 3%
Contacted another patient with diabetes for information/advice 1%
Continuous variables are provided as mean (range).
GP: general practitioner; PCP: primary care practitioner.
Table 2. Self-treated hypoglycaemia frequency in the last 30 days.
Global US Canada Japan UK Denmark Germany
Effective base (n) 2918 1777 153 347 308 52 281
Self-treated hypoglycaemia (%)
Incidence (events/last 30 days) 3.1 (1–30) 3.2 (1–30) 3.7 (1–10) 2.7 (1–8) 2.7 (1–20) 2.1 (1–4) 3.4 (1–14)
Patients with at least one event (n) 36% (1042) 38% (676) 33% (51) 27% (95) 37% (114) 38% (20) 31% (86)
5þ times in past 30 days (n) 6.8% (197) 7.3% (129) 9.2% (14) 5.5% (19) 4.5% (14) 0% (–) 7.5% (21)
Daytime self-treated hypoglycaemia (%)
Incidence (events/last 30 days) 2.3 (0–25) 2.3 (0–25) 2.6 (0–10) 2.5 (0–8) 1.9 (0–18) 1.8 (0–4) 2.5 (0–12)
Patients with at least one event (n) 30% (888) 32% (563) 29% (45) 27% (92) 31% (94) 35% (18) 27% (76)
5þ times in past 30 days (n)* 4.1% (119) 4.3% (77) 5.2% (8) 3.5% (12) 2.9% (9) 0% (–) 4.6% (13)
Nocturnal self-treated hypoglycaemia (%)
Incidence (events/last 30 days) 0.8 (0–15) 0.9 (0–15) 1.1 (0–6) 0.2 (0–2) 0.7 (0–15) 0.3 (0–2) 0.9 (0–5)
Patients with at least one event 13% (390) 15% (267) 16% (24) 5%(16) 14% (43) 10% (5) 12% (35)
5þ times in past 30 days (n)* 1.1% (34) 1.5% (26) 1.3% (2) 0% (-) 0.3% (1) 0% (-) 1.8% (5)
Incidence is provided as mean (range).
*Proportions for 5þ events may not add to the total as patients may have reported a mixture of daytime and night-time events in a 30 day period which would
therefore not be included in these sub-sets.
Table 3. Self-treated hypoglycaemia in the previous 30 days, by insulin regimen.
Basal insulin only Basal and bolus insulin p value
Effective base (n) 1400 1518
Self-treated hypoglycaemia (%)
Incidence (events/last 30 days) 2.9 (1–20) 3.2 (1–30)
Patients with at least one event 25% (355) 45% (687) 50.0001
Patients with 5 events (n) 4% (56) 9% (141) 50.0001
Daytime self-treated hypoglycaemia (%)
Incidence (events/last 30 days) 1.9 (0–12) 2.5 (0–25)
Patients with at least one event 20% (277) 40% (611) 50.0001
Nocturnal self-treated hypoglycaemia (%)
Incidence (events/last 30 days) 1.1 (0–15) 0.7 (0–12)
Patients with at least one event 10% (140) 16% (250) 50.0001
Incidence is provided as mean (range).
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situations) the characteristics that defined those at risk of
increased risk were the use of a basal–bolus regimen
regardless of gender or the use of a basal only regimen
with insulin injection dissatisfaction. The group at most
risk (defined by the ratio of the proportion of reported
hypoglycaemic events to the population proportion)
were those who reported moderate worry and a reduced
basal insulin dose in the last 30 days. This group of patients
represented 1.9% (57 patients) of the patient sample but
accounted for 5.4% of all reported episodes of self-treated
hypoglycaemia.
When considering all of the characteristics entered in
to the CHAID analysis, the profile of patients who are at
increased risk of self-treated hypoglycaemia are those
patients who expressed worry about hypoglycaemia, are
on more complex regimens, admit to reducing their basal
insulin dose (regardless of regimen), or are dissatisfied with
their insulin treatment. While these at risk patients com-
prise 38.2% of the surveyed population they accounted for
65.8% of all events.
Discussion
Patient reported self-treated hypoglycaemia remained
common despite treatment with basal insulin analogues,
and was associated with reduced patient functioning,
well-being and treatment interference.
The level of self-treated hypoglycaemia reported in this
paper is similar to that seen in other studies13,16. T2DM
patients have been shown to experience an average of 16
hypoglycaemic events per year17, and a recent survey
reported that over a third of patients had at least one day-
time, non-severe hypoglycaemic event in the last month6.
In addition, because as few as ten symptomatic non-severe
hypoglycaemic episodes per year may be considered
clinically relevant (increasing with the frequency of
episodes)18, the incidence of self-treated hypoglycaemia
reported in the study is believed to be at a clinically sig-
nificant level. This serves to reinforce the importance of
hypoglycaemia in the management of T2DM patients,
even in those using basal insulin analogues.
Moreover, the study found that patients using
basal–bolus insulin regimens were more likely to experi-
ence self-treated hypoglycaemia, which is in line with the
fact that T2DM patients are likely to have to intensify
their insulin regimen as -cell function declines.
This leads to a closer resemblance to the pathophysiology,
and hence hypoglycaemia rate, of insulin replacement
in T1DM as opposed to insulin supplementation in
early T2DM17,19.
Your relationship with your partner
Your night time routine
Your ability to socialise freely
Your ability to be spontaneous and change your plans
Taking part in sport and exercise
Attending work
 Performing at your best at work
Going on holiday or travelling
Your ability to commit to future events
Your ability to stay away overnight without planning in advance
Your usual daily routine (i.e. getting dressed, cleaning your teeth etc.)
Your ability to run errands
Dining out
 Your ability to focus and concentrate
Scheduling your day
14%
21%
27%
31%
36%
22%
32%
27%
20%
29%
18%
30%
24%
40%
24%
 Negatively Affected 
Proportion of patients negatively affected
Figure 2. The effect of self-treated hypoglycaemia on patient well-being and function.
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Findings from this study also indicate that self-treated
hypoglycaemic events affect diabetes management behav-
iours for both patients and physicians. Patients reported
both adjusting their basal dosing and increasing their
blood glucose monitoring in response to a self-treated
hypoglycaemic event. In addition, patients reported that
on some occasions they did not dose their basal insulin
as prescribed, as a preventative measure to avoid
NeverAbout a quarter of the time
About half of the timeAbout three quarters of the timeMost/all of the time
Switch the type of insulin they are on
Split the basal insulin into two doses
Reduce the dose of basal insulin long term
Reduce the dose of basal insulin temporarily
until they have restored hypoglycaemia
Advise the patient to reduce their insulin dose
if they plan to exercise
Review their diabetes more regularly
(increase blood glucose monitoring)
Educate the patient on how to recognise hypoglycaemia
Advise them on how to self-manage hypoglycaemia
Educate the patient on how to avoid hypoglycaemia
66% 17% 11% 5%1%
60% 17% 15% 5%2%
29% 24% 27% 16% 3%
30% 19% 23% 20% 8%
19% 16% 27% 29% 11%
15% 14% 24% 37% 10%
6%3% 18% 33% 40%
5%3% 16% 50% 26%
64% 16% 12% 6%1%
Proportion of prescribers 
Figure 3. Physician reports of recommended management approach for patients who experience self-treated hypoglycaemia.
FemaleMale1-3FemaleBasal & BolusBasal onlyBasal & Bolus
GenderGenderInsulin regimenInsulin regimen Mean satisfaction with
 insulin injections
Basal & BolusBasal onlyYesNoYesNo
Number of occasions worry
about experiencing a
hypoglycaemic event
Reduced a dose of your long-acting (basal) 
insulin only in the past 30 days
Reduced a dose of your long-acting (basal) 
insulin only in the past 30 days
Insulin regimen
1-3 9-65-4
100% 
100% 
28.5% 
27.6% 
18.7% 
23% 
13% 
12% 
9.8% 
4.6% 
3.7% 
2.2% 
6.1% 
2.4% 
15% 
10.6% 
9.6% 
8.7% 
5.7% 
3.7% 
5.4% 
1.9% 
38.5% 
23.5% 
10.3% 
8.9% 
3.1% 
1.7% 
28.2% 
14.6% 
13.4% 
8.2% 
14.8% 
6.4% 
 Top sections show proportion of total events 
 Bottom sections show proportion of patients
Figure 4. The CHAID tree showing combinations of patient characteristics that are associated with increased risk of self-treated hypoglycaemia in the last
30 days.
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nocturnal hypoglycaemia. The statistically significant
association between patients who missed, mistimed and
reduced basal insulin doses and those who experienced
self-treated hypoglycaemia, and the results of the
CHAID analysis, reinforce the directly reported impact
of self-treated hypoglycaemia on diabetes management.
Furthermore, despite the growing consensus amongst
clinician respondents to the study on the benefits of insu-
lin analogues compared to NPH in T2DM in terms of the
minimisation of hypoglycaemia risk, physicians reported
that they considered the risk of hypoglycaemia when
choosing which insulin to initiate in their patients, and
over half started patients at a lower than recommended
dose. These data support previous findings that physicians
would treat patients more aggressively if they were not
concerned about hypoglycaemia, as they believe that
their patients do not have adequate glucose control20.
These results are in agreement with the prior findings
that 43% of T2DM patients modify their insulin dose after
a mild or moderate hypoglycaemic episode21, and that
some patients modify their blood glucose levels by manip-
ulating their insulin dose due to fear of hypoglycaemia10.
However, it is unclear from our results whether the signif-
icant association between reported dosing irregularities
and self-treated hypoglycaemia was driven by dosing
adjustments as a precipitator (inappropriate dose reduction
due to fear of subsequent event) or as a consequence of a
self-treated hypoglycaemic event. Post-event adjustments
may, in some instances, be appropriate given that a sub-
stantial number of clinicians in our study reported that
they would recommend a reduction of basal insulin dose
(short or long term) or a splitting of basal insulin admin-
istration in response to self-treated hypoglycaemia. This
management approach by clinicians also reflects guideline
recommended trade-offs between glycaemic control and
hypoglycaemia22.
This study confirmed previous findings that a propor-
tion of patients utilise healthcare services as a consequence
of self-treatable hypoglycaemia8. These patient reports of
healthcare utilisation were substantiated by prescriber
feedback on contacts to them triggered by self-treated epi-
sodes. This resource utilisation has the potential to lead to
an increased cost in diabetes management, which is
already a large burden on international healthcare
systems6,8,11.
Further, the present study also confirmed findings that
self-treated hypoglycaemia impacts patient functioning,
lifestyle and well-being. The results of our CHAID analysis
point to a primary association between higher levels of self-
treated hypoglycaemia and patient worry about these
events. This is likely to relate to the increased worry expe-
rienced by patients who are having more hypoglycaemic
events and aligns with previous findings that over 29.9% of
patients who have experienced a mild or moderate hypo-
glycaemic event are more fearful about future episodes10.
In particular, nocturnal events caused more people to
worry than diurnal events and over half of patients were
concerned about their potential impact on long-term
health. The nocturnal hypoglycaemia and the concern
caused by these events affected patients’ usual daily func-
tioning. This aligns with previous research which has
shown that during the time spent recovering from a
single non-severe (self-treated) hypoglycaemic event
(which can be up to several days), patient functioning
and diabetes management are both negatively affected8.
Implications for clinical practice
There is a strong need to raise awareness about hypogly-
caemia so that all patients are able to recognise and deal
appropriately with this common complication of insulin
treatment, as well as a need to help identify subsets of
patients particularly at risk. The higher level of patient
worry and deliberately reported dosing modification
behaviour associated with nocturnal hypoglycaemia also
warrant particular clinical focus. While some of the asso-
ciated risk factors may be modifiable through appropriate
increases in education and social support, some may
involve consideration of the prescribed insulin regimen.
Given their higher risk of self-treated hypoglycaemia,
patients who have expressed worry about hypoglycaemia,
those on more complex regimens, those who admit to
reducing their basal dose (regardless of insulin regimen),
and those who have expressed dissatisfaction with their
insulin treatment (regardless of regimen) should be pro-
actively approached around the topic of hypoglycaemia to
establish the frequency and impact of these events with a
view to mitigating their potential impact on diabetes
management.
Limitations
This study was not designed to examine country specific
differences; however, self-treated hypoglycaemic events
were reported by patients regardless of country of origin,
gender or insulin regimen (basal only or basal and bolus).
Further study is needed to better understand these influ-
ences such as the potential role of cultural influences and
differing healthcare systems.
Additionally, the survey was designed to focus on self-
treated hypoglycaemia and basal insulin dosing irregulari-
ties in T2DM and as such did not provide an exhaustive list
of patient behaviours and characteristics for consideration
as part of the CHAID analysis. This means that some key
influences on the risk of self-treated hypoglycaemia may
have been missed such as typical diet and frequency of
blood glucose monitoring23.
It is also likely that dosing irregularities relating to
self-treated hypoglycaemia are underestimated in our
Current Medical Research & Opinion Volume 28, Number 12 December 2012
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dataset for several reasons. The surveys were self-com-
pleted and reported basal dosing irregularities that were
based on patient judgement which may have led to incor-
rect classifications. Additionally, recall bias may have led
to an underestimation of dosing irregularities particularly
when considered with the social bias against admitting
potentially inappropriate medication taking behaviour.
However, attempts were made to mitigate these factors,
definitions were always provided in the survey whenever
dosing irregularities were reported, data is presented focus-
ing on a 30 day period only and patients were informed
that results were confidential and were aware that the
data would not be shared with their physician.
Finally, the study was conducted via the internet which
may introduce certain biases particularly given that online
surveys select for respondents with internet access. While
the response rate may seem low, the respondents were tar-
geted via general population research panels which recruit
participants in order to be representative of the online
community and not through patient specific channels.
Therefore, the response rates seen in the survey were in
line with initial estimations used as part of the sample size
calculations. However, we acknowledge that this method-
ology may lead to over-representation of some key groups,
for example a slightly younger overall age group (although
the average in this cohort was 61 years), those still in
employment and those living in non-isolated situations.
It is also the case that the impact of the online nature of
the survey may vary by country. However, this bias was
considered minor as computer access and familiarity are
now very widely available within the participating
countries.
Conclusions
Self-treated hypoglycaemia is common in approximately
one third of patients using insulin analogue regimens and
is associated with clinically meaningful effects on patient
well-being and functioning, patient and physician man-
agement and healthcare utilisation. In response to self-
treated hypoglycaemia many patients increase their
blood glucose monitoring and some adjust their basal
insulin dosing. Additionally, nocturnal episodes of hypo-
glycaemia, which worry more patients than diurnal events,
also lead some people to keep their blood glucose at a
higher than appropriate level or adjust their basal insulin
dosing to proactively avoid events.
Research to further characterise patient attributes that
increase the risk of hypoglycaemia, including the associa-
tion between self-treated hypoglycaemia and dosing irreg-
ularities established by these results, is required. Despite
clinical awareness of hypoglycaemia, T2DM patients using
insulin analogues still need further support to reduce rates
of hypoglycaemia and improve their self-management of
hypoglycaemia risk.
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